Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J U Gutterman

Showing results (331-340 of 333) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 333 results.
Lancet (London, England)|April 24, 1976
Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracilG M Mavligit, J U Gutterman, M A Burgess, et al.
Cancer|December 1, 1975
Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes' C classification. Preliminary clinical resultsG M Mavligit, J U Gutterman, M A Burgess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervixA P Kudelka, T Levy, C F Verschraegen, et al.
Pageof 34

Showing results (331-340 of 333) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 333 results.
Lancet (London, England)|April 24, 1976
Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracilG M Mavligit, J U Gutterman, M A Burgess, et al.
Cancer|December 1, 1975
Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes' C classification. Preliminary clinical resultsG M Mavligit, J U Gutterman, M A Burgess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervixA P Kudelka, T Levy, C F Verschraegen, et al.
Pageof 34